Impairment of goodwill and adjustment of at-equity book value of minority interest in Envalior

  • LANXESS impairs parts of its goodwill
  • Adjustment of at-equity book value of minority interest in Envalior 
  • EBITDA pre exceptionals for Full Year 2023 remains within market expectations 
     
Cologne
During the preparation of annual financial statements for the year 2023, LANXESS identified an impairment requirement on goodwill amounting to EUR 413 million. The impairment incurred in the Business Units Flavors & Fragrances and Polymer Additives and reduces the goodwill recognized as part of the acquisitions. The reason for the impairment is a demand that has partly developed weaker than expected in the respective Business Units, especially for the years 2023 and 2024.  

In the course of the parallel and ongoing preparation of the financial statements at our joint venture Envalior, we also foresee the necessity of a material value reduction of our minority interest. This will likely result in a low to medium triple-digit million EUR amount. 

The impairment analyses are not completed and not yet finally audited. 

Neither the recognition of the impairment charges at LANXESS nor the reduction of the value of our minority interest have an effect on our EBITDA pre exceptionals, and are not cash relevant. 

LANXESS will report its results for Full Year 2023 on 14 March 2024. EBITDA pre exceptionals is expected to be in line with market expectations. The consensus (Vara) for EBITDA pre exceptionals is currently at EUR 510 million.
 

Information for editors:
All LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com. Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.

You can find further information concerning LANXESS chemistry at http://lanxess.com/en/Media/Stories.

MORE ABOUT THIS TOPIC

PRESS RELEASE
Vulkanox 4060

Sustainable Tire Protection: LANXESS Launches New Anti-Aging Agent as an Alternative for 6PPD

September 08, 2026
PRESS RELEASE
LANXESS manufactures an extensive product portfolio of lubricants. It includes additives and additive systems, synthetic base fluids and ready-to-use lubricants. 

LANXESS and KRAHN Chemie to Showcase Metal Working Fluid Solutions at Lubricant Expo Europe 2026

September 08, 2026
PRESS RELEASE
Woman working in Laboratory Kromm DL14

Saltigo showcases its phosgenation expertise and peptide synthesis reagents at CPHI Milan

September 07, 2026
PRESS RELEASE
In its battery laboratory, LANXESS tests the impact of different grades of iron oxide and iron phosphate in LFP materials directly within battery cells, thereby establishing a solid foundation for evaluating their performance.

New laboratory: LANXESS Strengthens Battery Expertise

September 04, 2026
PRESS RELEASE
Michael Ertl, Head of LANXESS' Inorganic Pigments business unit, and Rob Eek, Production Manager at Covestro in Krefeld-Uerdingen, stand in front of the new hydrogen pipeline serving LANXESS' iron oxide production plant.

LANXESS Powers Large-Scale Plant with Hydrogen

August 11, 2026